Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TriSalus Life Sciences, Inc. (TLSI : NSDQ)

• Company Description    TriSalus Life Sciences Inc. is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus Life Sciences Inc., formerly known as MedTech Acquisition Corporation, is based in CHICAGO. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $2.52 Daily Weekly Monthly 20 Day Moving Average: 514,006 shares Shares Outstanding: 61.31 (millions) Market Capitalization: $154.49 (millions) Beta: 0.56 52 Week High: $7.95 52 Week Low: $2.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.88% -47.32% 12 Week -45.34% -49.99% Year To Date -63.90% -67.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6272 W 91st Ave - Westminster,CO 80031 USA ph: 888-321-5212 fax: - investor.relations@trisaluslifesci.com http://www.trisaluslifesci.com

• General Corporate Information    Officers Mary Szela - Chief Executive Officer and Director Mats Wahlstrom - Director and Chairman of the Board David Patience - Chief Financial Officer Michael P. Stansky - Director Gary Gordon - Director Peer Information TriSalus Life Sciences, Inc. (BJCT) TriSalus Life Sciences, Inc. (CADMQ) TriSalus Life Sciences, Inc. (APNO) TriSalus Life Sciences, Inc. (UPDC) TriSalus Life Sciences, Inc. (IMTIQ) TriSalus Life Sciences, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 89680M101 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 61.31 Most Recent Split Date: (:1) Beta: 0.56 Market Capitalization: $154.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.06 Price/Cash Flow: - Price / Sales: 3.44 EPS Growth vs. Year Ago Period: 57.58% vs. Previous Quarter: -16.67% Sales Growth vs. Year Ago Period: -2.92% vs. Previous Quarter: -32.61% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -69.91 12/31/25 - -94.43 09/30/25 - -111.88 Current Ratio 03/31/26 - 5.78 12/31/25 - 2.80 09/30/25 - 3.05 Quick Ratio 03/31/26 - - 12/31/25 - 2.54 09/30/25 - 2.75 Operating Margin 03/31/26 - -71.69 12/31/25 - -74.11 09/30/25 - -90.70 Net Margin 03/31/26 - -60.85 12/31/25 - -86.88 09/30/25 - -98.45 Pre-Tax Margin 03/31/26 - -60.84 12/31/25 - -86.86 09/30/25 - -98.43 Book Value 03/31/26 - 0.21 12/31/25 - -0.68 09/30/25 - -0.54 Inventory Turnover 03/31/26 - 1.92 12/31/25 - 1.95 09/30/25 - 1.68 Debt-to-Equity 03/31/26 - 2.58 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - 72.09 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©